REGISTRATION IS OPEN FOR SOSV’S UPCOMING HEALTH TECH VC-FOUNDER MATCHUP. LEARN MORE

Be Part of the Revolution!

IndieBio is always looking for the next generation of early stage life sciences companies that will transform the future of human and planetary health. We review companies from across all different backgrounds, geographies, and sectors in the life sciences to invest and accelerate the next wave of innovation. IndieBio reviews applications on a rolling basis.

Click the button below to start the application on SOSV.com. What are the steps?

Choose SOSV as your Partner

IndieBio’s parent is SOSV, which has $910 million under management, and is consistently a Top Quartile VC. SOSV runs programs around the world in robotics, biotech, mobile ecommerce, fintech, automated manufacturing, food, and cryptocurrencies.

Accelerate
Your Science

A huge focus for every team while at IndieBio is going from bench to product in four months. This means making prototypes, getting them into hands of mentors and potential customers, and iterating off of their feedback over and over again.

Accelerate Your Business

We’re always pushing teams to close the distance between science and money. Your startup isn’t an academic project or research for a new paper. Becoming a real company means having a real product that people want and pay for.

Our Locations

For five years we have been in the heart of downtown San Francisco. We are located in the same building as HAX Boost, and the Revolution, which is a shared co-working space run by SOSV. Many of our graduated companies continue working at the Revolution where they can be amongst the most exciting startups to be found in the world.

How to Apply

  • Apply online, and someone from our team will read your application shortly to see if we’re a good fit.
  • If we’re interested in learning more, we’ll reach out for an interview (or more, if we really like you and your idea).
  • After we’ve determined that your idea is revolutionary and game-changing, we’ll send an offer to join our next cohort.